**Description**

**Source**
Mouse myeloma cell line, NS0-derived human Granzyme B protein Gly19-Tyr247, with a C-terminal 10-His tag
Accession # P10144

**N-terminal Sequence Analysis**
Gly19

**Structure / Form**
Pro form

**Predicted Molecular Mass**
27 kDa

**Specifications**

**SDS-PAGE**
37 kDa, reducing conditions

**Activity**
Measured by its ability to cleave a peptide substrate, t-Butyloxycaronyl-Ala-Ala-Asp-ThioBenzyl ester (Boc-AAD-SBzl), in the presence of 5,5'-Dithio-bis (2-nitrobenzoic acid) (DTNB).

The specific activity is >1,000 pmol/min/µg, as measured under the described conditions.

**Endotoxin Level**
<1.0 EU per 1 µg of the protein by the LAL method.

**Purity**
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

**Formulation**
Supplied as a 0.2 µm filtered solution in Tris and NaCl. See Certificate of Analysis for details.

**Activity Assay Protocol**

**Materials**
- Activation Buffer: 50 mM MES, 50 mM NaCl, pH 5.5
- Assay Buffer: 50 mM Tris, pH 7.5
- Recombinant Human Granzyme B (rhGranzyme B) (Catalog # 2906-SE)
- Recombinant Mouse Active Cathepsin C/DPPi (rmCathepsin C) (Catalog # 2336-CY)
- Substrate: t-Butyloxycaronyl-Ala-Ala-Asp-ThioBenzyl ester (SM Biochemicals LLC, Catalog # SMSB05), 10 mM stock in DMSO
- 5,5'-dithio-bis (2-nitrobenzoic acid) (DTNB) (Sigma, Catalog # D-8130), 10 mM stock in DMSO
- (optional) E-64 (Tocris, Catalog # 5208), 50 mM stock in DMSO
- 96-well Clear Plate (Costar, Catalog # 92592)
- Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent

**Assay**

1. Activate rhGranzyme B at 100 µg/mL with 10 µg/mL active rmCathepsin C in Activation Buffer.
2. Incubate at 37 °C for 4 hours. (Optional: use 10 μM E-64 in activation buffer to stop activating enzyme, this is not required under these conditions).
3. Dilute activated rhGranzyme B to 0.5 ng/µL in Assay Buffer.
4. Dilute Substrate to 200 µM in Assay Buffer containing 200 µM DTNB.
5. In a plate load 50 µL of 0.5 ng/µL rhGranzyme B. Include a Substrate Blank containing 50 µL of Assay Buffer.
6. Start the reaction by adding 50 µL of Substrate mixture to wells.
7. Read in kinetic mode for 5 minutes at an absorbance of 405 nm.
8. Calculate specific activity:

\[
\text{Specific Activity (pmol/min/µg)} = \frac{\text{Adjusted } V_{\text{max}} \times (\text{OD/min}) \times \text{well volume (L)} \times 10^{12} \text{ pmol/M}}{\text{ext. coeff} \times (\text{M}^{-1}\text{cm}^{-1}) \times \text{path corr}\times (\text{cm}) \times \text{amount of enzyme (µg)}}
\]

*Adjusted for Substrate Blank
**Using the extinction coefficient 13260 M$^{-1}$cm$^{-1}$
***Using the path correction 0.32 cm

**Final Assay Conditions**
<table>
<thead>
<tr>
<th>Per Well:</th>
</tr>
</thead>
<tbody>
<tr>
<td>rhGranzyme B: 0.025 µg</td>
</tr>
<tr>
<td>DTNB: 100 µM</td>
</tr>
<tr>
<td>Substrate: 100 µM</td>
</tr>
</tbody>
</table>

**Preparation and Storage**

**Shipping**
The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage**
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 6 months from date of receipt, -70 °C as supplied.
- 3 months, -70 °C under sterile conditions after opening.
Granzyme B is a member of the granzyme family of the serine proteases found specifically in the cytotoxic granules of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells (1, 2). Granzyme B plays an essential role in granule-mediated apoptosis and may have additional roles in rheumatoid arthritis and in bacterial and viral infections (3). It activates various caspases and cleaves proteins such as aggrecan (3). Human Granzyme B is synthesized as a precursor (247 residues) with a signal peptide (residues 1-18), a pro peptide (residues 19-20), and a mature chain (residues 21-247) (4-6). The rhGranzyme B consisting of residues 19-247 was expressed and purified. After being activated by active cathepsin C, rhGranzyme B cleaves a thioester substrate described previously (3).

References: